Leads in technological competitiveness through continuous R&D.
Novocellbio, which is taking off as a global leader in biotechnology with NK cell mass culture and activation technology, is strengthening its technological competitiveness through continuous R&D investment.
Novocellbio is researching and developing various immune cell treatment technologies by investing more than 20% of our sales in R&D.
Novocellbio are further strengthening our global technology leadership through
various research activities conducted jointly with R&D centers, hospital immunotherapy centers, and research and development centers at universities.